Supriya Lifescience

Supriya Lifescience Debt/EBITDA

The Total Debt to EBITDA Ratio of Supriya Lifescience (SUPRIYA.NS) as of Oct 16, 2026 is 0.02. In the previous year, Total Debt to EBITDA Ratio was 0.02 — a change of -1.19% (lower).

Debt/EBITDA

0.02

YoY

-1.19%

Last updated:

Total Debt to EBITDA Ratio of Supriya Lifescience is 2026 0.02 . Total Debt to EBITDA Ratio of Supriya Lifescience was 2025 0.02 . It decreases by -1.19% lower compared to the previous year.

The Supriya Lifescience Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
1.39 INR
Jan 1, 2020
0.76 INR
Jan 1, 2021
0.42 INR
Jan 1, 2022
0.12 INR
Jan 1, 2023
0.16 INR
Jan 1, 2024
0.03 INR
Jan 1, 2025
0.02 INR
Jan 1, 2026
0.02 INR
The Supriya Lifescience Debt/EBITDA history
YEARDebt/EBITDAYoY
0.02-1.19%
0.02-33.49%
0.03-81.78%
0.16+32.56%
0.12-70.66%
0.42-44.19%
0.76-45.57%
1.39-76.55%
5.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd is a pharmaceutical company based in Mumbai, India, operating within the healthcare sector. The company specializes in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), with a focus on niche therapeutic segments. It employs 392 full-time staff and completed its initial public offering (IPO) on December 28, 2021. The firm's manufacturing facilities are located in Maharashtra, and it exports products to approximately 86 countries. Its product portfolio includes APIs for antihistamines, anesthetics, anti-asthma treatments, and other therapeutic areas such as analgesics and vitamins. Specific products mentioned include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride. The company is engaged in the production of bulk drugs and pharmaceutical chemicals, serving global markets through its export activities. It operates with a focus on niche API products, addressing specific therapeutic needs across multiple categories. The company's website is https://supriyalifescience.com/. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Total Debt to EBITDA Ratio of Supriya Lifescience is 0.02 in 2026.

Total Debt to EBITDA Ratio of Supriya Lifescience changed from 0.02 to 0.02, representing a -1.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Supriya Lifescience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Supriya Lifescience

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Supriya Lifescience